Message #48 From:
NewsBot Date: December 8, 2005 03:51:00 AM
CLXN News CLX Investment Company Announces Distribution for Zonda Infectious Disease Test Throughout Sweden and Norway
TEMECULA, Calif.--(BUSINESS WIRE)--Dec. 8, 2005--CLX Investment Company, Inc. (OTCBB:CLXN) today announced that portfolio investment Zonda, Inc., a privately held company that specializes in test products that serve the medical diagnostic, bacterial food testing and environmental surfaces testing markets, has secured distribution for pharmaceutical locations throughout Norway and Sweden.
Zonda has entered into an agreement that will expand the distribution of the company's HandiLab-C test for Chlamydia in Scandinavia. The HandiLab-C test is currently distributed to pharmacies across Norway, and beginning on February 1, 2006, will begin selling to all pharmacies in Sweden.
"This is another significant step in the expansion of distribution of Zonda's products into new markets around the world," said Tammy D. Dunn, chief executive officer of CLX Investment Company. "The HandiLab-C self-test for Chlamydia is the only over-the-counter test that carries the CE mark, which signifies that the product complies with the essential requirements of the relevant health, safety and environmental protection legislations in Europe and can therefore be legally placed on the market. This, as well as the fact that the HandiLab-C is marketed as superior to its competition due to its comparable accuracy (compared directly to PCR testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness, is expected to promote brisk sales for both over-the-counter and professional point-of-care use in European markets."
Zonda's product line also includes diagnostic testing products for the detection of gonorrhea, yeast and Strep A, which all carry CE marks for professional point-of-care use.
"As distribution of these products becomes more widespread in Europe and with Zonda pursuing regulatory approvals in both the United States and China, we expect the value of our investment in Zonda to significantly increase," added Ms. Dunn.
To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.asp.
About the Company
CLX Investment Company (www.clxinvestments.com) has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.
CLX has acquired a 49% interest in eStrategy Solutions, Inc. (www.clxinvestments.com/estrategysolutions), a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. The Company has made an investment in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards. CLX holds a 20% equity interest in Zonda, Inc. (www.zondainc.com), a privately held company that specializes in test products that serve the medical diagnostic, bacterial food testing and environmental surfaces testing markets.
All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.
